ACADACADIA Pharmaceuticals Inc.
$19.78-19% 1Y
$19.78
$19.5752 weeks$30.58
ACAD in its own filings
ACAD's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
376
Events found in the filings · across 1,377 filings · the record starts in 2004
- Hard flags
- 1
Hard flags
- Most recent filing
- Sep 24, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 11, 2004
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 4, 2026
- Change in certifying accountant2 occurrences
- 2015-03-30
- Delisting notice / listing-rule failure3 occurrences
- 2010-11-09
- SEC comment-letter activity8 occurrences
- 2025-05-21
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 24, 2026On September 24, 2026, the Company announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with ADP. For the primary endpoint of change from baseline in the Scale for the …Regulation FD disclosure · Form 8-K
- Sep 11, 2026On August 24, 2026, the United States District Court for the Southern District of California (the “Court”) preliminarily approved the settlement (“Settlement”) of the stockholder derivative action captioned Kanner et al. v.Other event · Form 8-K
- Aug 4, 2026Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results.Earnings release · press release
- May 29, 2026On May 29, 2026, Acadia Pharmaceuticals Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
- May 6, 2026Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance.Earnings release · press release
- May 1, 2026On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.Director or officer change · Form 8-K
- Mar 5, 2026On March 3, 2026, the board of directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jonathan M. Poole to the Board to fill a vacancy and as a member of the Audit Committee of the Board, effective …Director or officer change · Form 8-K
- Feb 25, 2026Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview.Earnings release · press release
- Nov 5, 2025Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview.Earnings release · press release
- Nov 3, 2025On October 28, 2025, Daniel B. Soland notified the Board of Directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) of his resignation from the Board and from his positions as a member and Chair of the Nominating and Corporate Governance Committee of the Board, effective as of October 30, 2025.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…